Generic Name: elafibranor

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: NAFLD/NASH Medications

Company: Genfit

Approval Status: Experimental

Generic Version Available: No

Experimental Code: GFT505

General Info

Elafibranor is an agonist of the peroxisome proliferator−activated receptor-α and peroxisome proliferator−activated receptor-δ. It is currently in Phase 3 clinical trials for treatment of non-alcoholic steatohepatitis (NASH).


Dosing Info: N/A

Side Effects


Last Reviewed: February 4, 2019